Abstract:Biological therapies play an increasing role in cancer treatment, although the number of naked antibodies showing clinical efficacy as single agent remains limited. One way to enhance therapeutic potential of antibodies is to conjugate them to small molecule drugs. This combination is expected to bring together the benefits of highly potent drugs on the one hand and selective binders of specific tumor antigens on the other hand. However, designing an ADC is more complex than a simple meccano game, requiring thoughtful combination of antibody, linker, and drugs in the context of a target and a defined cancer indication. Lessons learned from the first-generation antibody–drug conjugate (ADC) and improvement of the technology guided the design of improved compounds which are now in clinical trials. Brentuximab vedotin (Adcetris®), an anti-CD30 antibody conjugated to a potent microtubule inhibitor for the treatment of Hodgkin’s lymphoma and anaplastic large cell lymphomas, is the only marketed ADC today. A total of 27 ADC are currently undergoing clinical trials in both hematological malignancies and solid tumor indications. Among them, T-DM1 (trastuzumab emtansine), an ADC comprised of trastuzumab conjugated to DM1, via a non-cleavable linker, is showing very promising results in phase III for the treatment of HER2-positive refractory/relapsed metastatic breast cancer. Other compounds, such as CMC-544, SAR3419, CDX-011, PSMA-ADC, BT-062, and IMGN901 currently in clinical trials, targeting varied antigens and bearing different linker and drugs, contribute to the learning curve of ADC, as do the discontinued ADC. Current challenges include improvement of the therapeutic index, linked to a careful selection of the targets, a better understanding of ADC mechanism of action, the management and understanding of ADC off-target toxicities, as well as the selection of appropriate clinical settings (patient selection, dosing regimen) where these molecules can bring highest clinical benefit.

Optimizing Solid Tumor Treatment with Antibody–drug Conjugates Using Agent-Based Modeling: Considering the Role of a Carrier Dose and Payload Class

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload

Prospects and progress of antibody-drug conjugates in solid tumor therapies

Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data

Analyze Impact of Tumor-Associated Kinetics on Antibody Delivery in Solid Tumors with a Physiologically Based Pharmacokinetics/pharmacodynamics Model.

Antibody-drug conjugates in solid tumors: a look into novel targets

Exploring the Sensitivity of Antibody-Drug Conjugate Efficacy to the Selection of Payload, Antibody, and Cell line

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy

Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis

Reforming Solid Tumor Treatment: the Emerging Potential of Smaller Format Antibody-Drug Conjugate.

Optimizing the safety of antibody–drug conjugates for patients with solid tumours

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

Antibody-drug conjugates in solid tumors: a new frontier

CHAPTER 2. Design Factors Important for Antibody–Drug Conjugate (ADC) Payloads

Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review

Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions